Importer of Controlled Substances Application: VHG Labs dba LGC Standards, 24861-24865 [2024-07525]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 69 / Tuesday, April 9, 2024 / Notices
investigation is sold at the retail level)
representative consumer organizations
have the right to appear as parties in
Commission antidumping duty and
countervailing duty investigations. The
Secretary will prepare a public service
list containing the names and addresses
of all persons, or their representatives,
who are parties to these investigations
upon the expiration of the period for
filing entries of appearance.
Limited disclosure of business
proprietary information (BPI) under an
administrative protective order (APO)
and BPI service list.—Pursuant to
§ 207.7(a) of the Commission’s rules, the
Secretary will make BPI gathered in
these investigations available to
authorized applicants representing
interested parties (as defined in 19
U.S.C. 1677(9)) who are parties to the
investigations under the APO issued in
the investigations, provided that the
application is made not later than seven
days after the publication of this notice
in the Federal Register. A separate
service list will be maintained by the
Secretary for those parties authorized to
receive BPI under the APO.
Conference.—The Office of
Investigations will hold a staff
conference in connection with the
preliminary phase of these
investigations beginning at 9:30 a.m. on
Wednesday, April 24, 2024. Requests to
appear at the conference should be
emailed to preliminaryconferences@
usitc.gov (DO NOT FILE ON EDIS) on or
before Monday, April 22, 2024. Please
provide an email address for each
conference participant in the email.
Information on conference procedures,
format, and participation, including
guidance for requests to appear as a
witness via videoconference, will be
available on the Commission’s Public
Calendar (Calendar (USITC) | United
States International Trade Commission).
A nonparty who has testimony that may
aid the Commission’s deliberations may
request permission to participate by
submitting a short statement.
Please note the Secretary’s Office will
accept only electronic filings during this
time. Filings must be made through the
Commission’s Electronic Document
Information System (EDIS, https://
edis.usitc.gov). No in-person paperbased filings or paper copies of any
electronic filings will be accepted until
further notice.
Written submissions.—As provided in
§§ 201.8 and 207.15 of the
Commission’s rules, any person may
submit to the Commission on or before
5:15 p.m. on April 29, 2024, a written
brief containing information and
arguments pertinent to the subject
matter of the investigations. Parties shall
VerDate Sep<11>2014
19:57 Apr 08, 2024
Jkt 262001
file written testimony and
supplementary material in connection
with their presentation at the conference
no later than noon on April 23, 2024.
All written submissions must conform
with the provisions of § 201.8 of the
Commission’s rules; any submissions
that contain BPI must also conform with
the requirements of §§ 201.6, 207.3, and
207.7 of the Commission’s rules. The
Commission’s Handbook on Filing
Procedures, available on the
Commission’s website at https://
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf, elaborates
upon the Commission’s procedures with
respect to filings.
In accordance with §§ 201.16(c) and
207.3 of the rules, each document filed
by a party to the investigations must be
served on all other parties to the
investigations (as identified by either
the public or BPI service list), and a
certificate of service must be timely
filed. The Secretary will not accept a
document for filing without a certificate
of service.
Certification.—Pursuant to § 207.3 of
the Commission’s rules, any person
submitting information to the
Commission in connection with these
investigations must certify that the
information is accurate and complete to
the best of the submitter’s knowledge. In
making the certification, the submitter
will acknowledge that any information
that it submits to the Commission
during these investigations may be
disclosed to and used: (i) by the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of these or related investigations or
reviews, or (b) in internal investigations,
audits, reviews, and evaluations relating
to the programs, personnel, and
operations of the Commission including
under 5 U.S.C. Appendix 3; or (ii) by
U.S. government employees and
contract personnel, solely for
cybersecurity purposes. All contract
personnel will sign appropriate
nondisclosure agreements.
Authority: These investigations are
being conducted under authority of
Title VII of the Tariff Act of 1930; this
notice is published pursuant to § 207.12
of the Commission’s rules.
By order of the Commission.
Issued: April 3, 2024.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2024–07458 Filed 4–8–24; 8:45 am]
BILLING CODE 7020–02–P
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
24861
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1353]
Importer of Controlled Substances
Application: VHG Labs dba LGC
Standards
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
VHG Labs dba LGC Standards
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to Supplementary
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before May 9, 2024. Such persons
may also file a written request for a
hearing on the application on or before
May 9, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on February 27, 2024,
VHG labs dba LGC Standards, 3
Perimeter Road, Manchester, New
Hampshire 03103–3341, applied to be
registered as an importer of the
SUMMARY:
E:\FR\FM\09APN1.SGM
09APN1
24862
Federal Register / Vol. 89, No. 69 / Tuesday, April 9, 2024 / Notices
following basic class(es) of controlled
substance(s):
ddrumheller on DSK120RN23PROD with NOTICES1
Controlled substance
Amineptine (7-[(10,11-dihydro-5Hdibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid) ................................................................
Mesocarb (N-phenyl-N′-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate) ......................................................
3-Fluoro-N-methylcathinone (3-FMC) .............................................................................................................................................
Cathinone .......................................................................................................................................................................................
Methcathinone ................................................................................................................................................................................
4-Fluoro-N-methylcathinone (4-FMC) 1238 I N .............................................................................................................................
Para-Methoxymethamphetamine (PMMA), 1-(4-methoxyphenyl)-N-methylpropan-2-amine .........................................................
Pentedrone (a-methylaminovalerophenone) ..................................................................................................................................
4-Methyl-N-ethylcathinone (4-MEC) ...............................................................................................................................................
Naphyrone ......................................................................................................................................................................................
N-Ethylamphetamine ......................................................................................................................................................................
Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine) 1478 I N ......................................................................................
N,N-Dimethylamphetamine ............................................................................................................................................................
Fenethylline ....................................................................................................................................................................................
Aminorex ........................................................................................................................................................................................
4-Methylaminorex (cis isomer) .......................................................................................................................................................
4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-1595 I N methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5-(4methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine).
Gamma Hydroxybutyric Acid ..........................................................................................................................................................
Methaqualone .................................................................................................................................................................................
Mecloqualone .................................................................................................................................................................................
Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6Hthieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine ................................................
Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4Hbenzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) ...........................................
Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4Hbenzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine ..................................................
Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine ..........................................
Diclazepam (7-chloro-5-(2-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one ...............................
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) ..................................................................................................................
SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ................................................................
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ............................
5-Fluoro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ................................
AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .....................................
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) ......................................................................................................................................
FUB-AMB, MMB-FUBINACA, AMB-FUBINACA (2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3-methylbutanoate) ............
AB-PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .........................................................
THJ-2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) ................................................................................
5F-AB-PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluropentyl)-1H-indazole-3-carboximide) ........................................
AB-CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) ...............................
5F-ADB, 5F-MDMB-PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .......................
5F-MDMB-PICA (methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) ...............................................
MDMB-CHMICA, MMB-CHMINACA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) ..........
APINACA and AKB48 (N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide) ...........................................................................
5F-APINACA, 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ...................................................
JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) ..................................................................................................................
4-CN-CUML-BUTINACA, 4-cyano-CUMYL-BUTINACA, 4-CN-CUMYL BINACA, CUMYL-4CN-BINACA, SGT-78 (1-(4cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide).
SR-19 (Also known as RCS-4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole) ....................................................................................
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) .............................................................................................
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) .....................................................................................................................
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .................................................................................
JWH-073 (1-Butyl-3-(1-naphthoyl)indole) .......................................................................................................................................
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ..........................................................................................................
AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) ......................................................................................................................
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) .....................................................................................................................
PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) .................................................................................................................
5F-PB-22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) .............................................................................................
N-ethylhexedrone 7246 I N ............................................................................................................................................................
Alpha-ethyltryptamine .....................................................................................................................................................................
Ibogaine ..........................................................................................................................................................................................
2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine) ......................................................................................
CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) ................................................................................
CP-47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol) ..........................................................
Lysergic acid diethylamide .............................................................................................................................................................
2C-T-7 (2,5-Dimethoxy-4-(n)-propylthiophenethylamine ................................................................................................................
Marihuana Extract ..........................................................................................................................................................................
Marihuana .......................................................................................................................................................................................
Tetrahydrocannabinols ...................................................................................................................................................................
Mescaline .......................................................................................................................................................................................
2C-T-2 (2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine ) ...........................................................................................................
3,4,5-Trimethoxyamphetamine .......................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine ............................................................................................................................................
VerDate Sep<11>2014
19:57 Apr 08, 2024
Jkt 262001
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
E:\FR\FM\09APN1.SGM
09APN1
Drug
code
Schedule
1219
1227
1233
1235
1237
1238
1245
1246
1249
1258
1475
1478
1480
1503
1585
1590
1595
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
2010
2565
2572
2780
2785
2786
2788
2789
6250
7008
7010
7011
7012
7019
7021
7023
7024
7025
7031
7034
7041
7042
7048
7049
7081
7089
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
7104
7118
7122
7144
7173
7200
7201
7203
7222
7225
7246
7249
7260
7286
7297
7298
7315
7348
7350
7360
7370
7381
7385
7390
7391
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
24863
Federal Register / Vol. 89, No. 69 / Tuesday, April 9, 2024 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
Controlled substance
4-Bromo-2,5-dimethoxyphenethylamine .........................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine ............................................................................................................................................
2,5-Dimethoxyamphetamine ...........................................................................................................................................................
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole) .....................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine ...............................................................................................................................................
3,4-Methylenedioxyamphetamine ...................................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine ......................................................................................................................................
3,4-Methylenedioxymethamphetamine ...........................................................................................................................................
4-Methoxyamphetamine .................................................................................................................................................................
5-Methoxy-N-N-dimethyltryptamine ................................................................................................................................................
Alpha-methyltryptamine ..................................................................................................................................................................
Bufotenine ......................................................................................................................................................................................
Diethyltryptamine ............................................................................................................................................................................
Dimethyltryptamine .........................................................................................................................................................................
Psilocybin .......................................................................................................................................................................................
Psilocyn ..........................................................................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ..................................................................................................................................................
1-(1-Phenylcyclohexyl)pyrrolidine ...................................................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine ..............................................................................................................................................
N-Benzylpiperazine ........................................................................................................................................................................
4-MePPP (4-Methyl-alphapyrrolidinopropiophenone) ....................................................................................................................
2C-D (2-(2,5-Dimethoxy-4-methylphenyl) ethanamine) .................................................................................................................
2C-E (2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine) .....................................................................................................................
2C-I 2-(4-iodo-2,5-dimethoxyphenyl) ethanamine) .........................................................................................................................
2C-C 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine) ...................................................................................................................
2C-N (2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine) ....................................................................................................................
2C-P (2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine) .............................................................................................................
2C-T-4 (2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine) ....................................................................................................
MDPV (3,4-Methylenedioxypyrovalerone) ......................................................................................................................................
25B-NBOMe (2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine) ....................................................................
25C-NBOMe (2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine) ....................................................................
25I-NBOMe (2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine) .........................................................................
Methylone (3,4-Methylenedioxy-N-methylcathinone) .....................................................................................................................
Butylone ..........................................................................................................................................................................................
Pentylone ........................................................................................................................................................................................
N-Ethypentylone, ephylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one) ....................................................................
alpha-pyrrolidinopentiophenone (a-PVP) .......................................................................................................................................
alpha-pyrrolidinobutiophenone (a-PBP) .........................................................................................................................................
Ethylone ..........................................................................................................................................................................................
AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole) ...................................................................................................................
Codeine-N-oxide .............................................................................................................................................................................
Desomorphine ................................................................................................................................................................................
Dihydromorphine ............................................................................................................................................................................
Difenoxin .........................................................................................................................................................................................
Heroin .............................................................................................................................................................................................
Morphine-N-oxide ...........................................................................................................................................................................
Nicomorphine .................................................................................................................................................................................
Normorphine ...................................................................................................................................................................................
Pholcodine ......................................................................................................................................................................................
Drotebanol ......................................................................................................................................................................................
U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide) ..............................................................................
AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)) .................................................................................
MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine)) ..................................................................................................................
Acetylmethadol ...............................................................................................................................................................................
Alphameprodine .............................................................................................................................................................................
Alphamethadol ................................................................................................................................................................................
Benzethidine ...................................................................................................................................................................................
Betameprodine ...............................................................................................................................................................................
Clonitazene .....................................................................................................................................................................................
Dextromoramide .............................................................................................................................................................................
Isotonotazene (N,N-diethyl-2-(2-(4 isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine) ...........................................
Dimenoxadol ...................................................................................................................................................................................
Dimepheptanol ...............................................................................................................................................................................
Dimethylthiambutene ......................................................................................................................................................................
Dioxaphetyl butyrate .......................................................................................................................................................................
Dipipanone .....................................................................................................................................................................................
Etonitazene .....................................................................................................................................................................................
Ketobemidone ................................................................................................................................................................................
Levomoramide ................................................................................................................................................................................
Noracymethadol .............................................................................................................................................................................
Norlevorphanol ...............................................................................................................................................................................
Normethadone ................................................................................................................................................................................
VerDate Sep<11>2014
19:57 Apr 08, 2024
Jkt 262001
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
E:\FR\FM\09APN1.SGM
09APN1
Drug
code
Schedule
7392
7395
7396
7398
7399
7400
7404
7405
7411
7431
7432
7433
7434
7435
7437
7438
7439
7455
7458
7470
7493
7498
7508
7509
7518
7519
7521
7524
7532
7535
7536
7537
7538
7540
7541
7542
7543
7545
7546
7547
7694
9053
9055
9145
9168
9200
9307
9312
9313
9314
9335
9547
9551
9560
9601
9604
9605
9606
9608
9612
9613
9614
9617
9618
9619
9621
9622
9624
9628
9629
9633
9634
9635
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
24864
Federal Register / Vol. 89, No. 69 / Tuesday, April 9, 2024 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
Controlled substance
Piritramide ......................................................................................................................................................................................
Properidine .....................................................................................................................................................................................
Racemoramide ...............................................................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine .....................................................................................................................................
Tilidine ............................................................................................................................................................................................
Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1Hbenzimidazol-1-yl)ethan-1-amine ..................................................
Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine) ................................................
+Para-Fluorofentanyl ......................................................................................................................................................................
3-Methylfentanyl .............................................................................................................................................................................
Alpha-methylfentanyl ......................................................................................................................................................................
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) ..............................................................................................
Butyryl Fentanyl ..............................................................................................................................................................................
4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide) ........................................................
Beta-hydroxyfentanyl ......................................................................................................................................................................
Beta-hydroxy-3-methylfentanyl .......................................................................................................................................................
3-Methylthiofentanyl .......................................................................................................................................................................
Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide) ............................................................................
Thiofentanyl ....................................................................................................................................................................................
Beta-hydroxythiofentanyl ................................................................................................................................................................
Ocfentanil .......................................................................................................................................................................................
beta′-Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide; also known as b′-phenyl fentanyl; 3phenylpropanoyl fentanyl).
N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide .........................................................................................
Crotonyl fentanyl ((E-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide) ................................................................................
Cyclopropyl Fentanyl ......................................................................................................................................................................
ortho-Fluorobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide; also known as 2-fluorobutyryl
fentanyl).
Fentanyl related-compounds as defined in 21 CFR 1308.11(h) ....................................................................................................
Amphetamine .................................................................................................................................................................................
Methamphetamine ..........................................................................................................................................................................
Lisdexamfetamine ..........................................................................................................................................................................
Phenmetrazine ...............................................................................................................................................................................
Amobarbital ....................................................................................................................................................................................
Pentobarbital ..................................................................................................................................................................................
Secobarbital ....................................................................................................................................................................................
Glutethimide ...................................................................................................................................................................................
Nabilone .........................................................................................................................................................................................
Phencyclidine .................................................................................................................................................................................
ANPP (4-Anilino-N-phenethyl-4-piperidine) ....................................................................................................................................
Norfentanyl (N-phenyl-N-(piperidin-4-yl) propionamide) ................................................................................................................
Phenylacetone ................................................................................................................................................................................
Alphaprodine ..................................................................................................................................................................................
Cocaine ..........................................................................................................................................................................................
Codeine ..........................................................................................................................................................................................
Dihydrocodeine ...............................................................................................................................................................................
Oxycodone .....................................................................................................................................................................................
Hydromorphone ..............................................................................................................................................................................
Diphenoxylate .................................................................................................................................................................................
Ecgonine .........................................................................................................................................................................................
Ethylmorphine .................................................................................................................................................................................
Hydrocodone ..................................................................................................................................................................................
Levomethorphan .............................................................................................................................................................................
Levorphanol ....................................................................................................................................................................................
Isomethadone .................................................................................................................................................................................
Meperidine ......................................................................................................................................................................................
Meperidine intermediate-A .............................................................................................................................................................
Meperidine intermediate-B .............................................................................................................................................................
Meperidine intermediate-C .............................................................................................................................................................
Oliceridine (N-[(3-methoxythiophen-2yl)methyl] ({2-[9r)-9-(pyridin-2-yl)-6-oxaspiro[4.5] decan-9-yl] ethyl {time})amine fumarate).
Methadone ......................................................................................................................................................................................
Methadone intermediate .................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) .............................................................................................................................
Morphine .........................................................................................................................................................................................
Oripavine ........................................................................................................................................................................................
Thebaine .........................................................................................................................................................................................
Levo-alphacetylmethadol ................................................................................................................................................................
Oxymorphone .................................................................................................................................................................................
Noroxymorphone ............................................................................................................................................................................
Phenazocine ...................................................................................................................................................................................
Racemethorphan ............................................................................................................................................................................
Alfentanil .........................................................................................................................................................................................
Remifentanil ....................................................................................................................................................................................
VerDate Sep<11>2014
19:57 Apr 08, 2024
Jkt 262001
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
E:\FR\FM\09APN1.SGM
09APN1
Drug
code
Schedule
9642
9644
9645
9661
9750
9757
9759
9812
9813
9814
9821
9822
9824
9830
9831
9833
9834
9835
9836
9838
9842
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
9843
9844
9845
9846
I
I
I
I
9850
1100
1105
1205
1631
2125
2270
2315
2550
7379
7471
8333
8366
8501
9010
9041
9050
9120
9143
9150
9170
9180
9190
9193
9210
9220
9226
9230
9232
9233
9234
9245
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
9250
9254
9273
9300
9330
9333
9648
9652
9668
9715
9732
9737
9739
II
II
II
II
II
II
II
II
II
II
II
II
II
24865
Federal Register / Vol. 89, No. 69 / Tuesday, April 9, 2024 / Notices
Controlled substance
Sufentanil ........................................................................................................................................................................................
Carfentanil ......................................................................................................................................................................................
Tapentadol ......................................................................................................................................................................................
Fentanyl ..........................................................................................................................................................................................
DEPARTMENT OF JUSTICE
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
Drug Enforcement Administration
SUPPLEMENTARY INFORMATION:
The company plans to import the
listed controlled substances for
distribution for analytical testing
purposes. No other activities for these
drug codes are authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–07525 Filed 4–8–24; 8:45 am]
BILLING CODE P
In
accordance with 21 CFR 1301.34(a), this
is notice that on March 6, 2024, Lyndra
Therapeutics, 60 Westview Street,
Lexington, Massachusetts 02421–3108,
applied to be registered as an importer
of the following basic class(es) of
controlled substance(s):
[Docket No. DEA–1355]
Importer of Controlled Substances
Application: Lyndra Therapeutics
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Lyndra Therapeutics has
applied to be registered as an importer
of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before May 9, 2024. Such persons
may also file a written request for a
hearing on the application on or before
May 9, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
19:57 Apr 08, 2024
Jkt 262001
Drug
code
Controlled substance
Methadone ....................
I
9250
Schedule
III
The company plans to import the
above controlled substance for use in
preclinical research and human clinical
trials. No other activity for this drug
code is authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–07529 Filed 4–8–24; 8:45 am]
BILLING CODE P
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
Drug
code
Schedule
9740
9743
9780
9801
II
II
II
II
DEPARTMENT OF JUSTICE
[OMB Number 1123–1NEW]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; New
Collection; Application for Remission
of Financial Penalties
Office of the Pardon Attorney,
Department of Justice.
ACTION: 60-Day notice.
AGENCY:
The Office of the Pardon
Attorney, Department of Justice (DOJ),
will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until June
10, 2024.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Kira Gillespie, Deputy Pardon Attorney,
Office of the Pardon Attorney, 950
Pennsylvania Avenue NW, Main
Justice—RFK Building, Washington, DC
20530; uspardon.attorney@usdoj.gov;
202–616–6070.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the Bureau of Justice
Statistics, including whether the
information will have practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
SUMMARY:
E:\FR\FM\09APN1.SGM
09APN1
]]>Agencies
[Federal Register Volume 89, Number 69 (Tuesday, April 9, 2024)]
[Notices]
[Pages 24861-24865]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07525]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1353]
Importer of Controlled Substances Application: VHG Labs dba LGC
Standards
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: VHG Labs dba LGC Standards has applied to be registered as an
importer of basic class(es) of controlled substance(s). Refer to
Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
May 9, 2024. Such persons may also file a written request for a hearing
on the application on or before May 9, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on February 27, 2024, VHG labs dba LGC Standards, 3
Perimeter Road, Manchester, New Hampshire 03103-3341, applied to be
registered as an importer of the
[[Page 24862]]
following basic class(es) of controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Amineptine (7-[(10,11-dihydro- 1219 I
5Hdibenzo[a,d]cyclohepten-5-
yl)amino]heptanoic acid).
Mesocarb (N-phenyl-N'-(3-(1-phenylpropan- 1227 I
2-yl)-1,2,3-oxadiazol-3-ium-5-
yl)carbamimidate).
3-Fluoro-N-methylcathinone (3-FMC)...... 1233 I
Cathinone............................... 1235 I
Methcathinone........................... 1237 I
4-Fluoro-N-methylcathinone (4-FMC) 1238 1238 I
I N.
Para-Methoxymethamphetamine (PMMA), 1-(4- 1245 I
methoxyphenyl)-N-methylpropan-2-amine.
Pentedrone ([alpha]- 1246 I
methylaminovalerophenone).
4-Methyl-N-ethylcathinone (4-MEC)....... 1249 I
Naphyrone............................... 1258 I
N-Ethylamphetamine...................... 1475 I
Methiopropamine (N-methyl-1-(thiophen-2- 1478 I
yl)propan-2-amine) 1478 I N.
N,N-Dimethylamphetamine................. 1480 I
Fenethylline............................ 1503 I
Aminorex................................ 1585 I
4-Methylaminorex (cis isomer)........... 1590 I
4,4'-Dimethylaminorex (4,4'-DMAR; 4,5- 1595 I
dihydro-4-1595 I N methyl-5-(4-
methylphenyl)-2-oxazolamine; 4-methyl-5-
(4-methylphenyl)-4,5-dihydro-1,3-oxazol-
2-amine).
Gamma Hydroxybutyric Acid............... 2010 I
Methaqualone............................ 2565 I
Mecloqualone............................ 2572 I
Etizolam (4-(2-chlorophenyl)-2-ethyl-9- 2780 I
methyl-6Hthieno[3,2-
f][1,2,4]triazolo[4,3-a][1,4]diazepine.
Flualprazolam (8-chloro-6-(2- 2785 I
fluorophenyl)-1-methyl-
4Hbenzo[f][1,2,4]triazolo[4,3-
a][1,4]diazepine).
Clonazolam (6-(2-chlorophenyl)-1-methyl- 2786 I
8-nitro-4Hbenzo[f][1,2,4]triazolo[4,3-
a][1,4]diazepine.
Flubromazolam (8-bromo-6-(2- 2788 I
fluorophenyl)-1-methyl4H-
benzo[f][1,2,4]triazolo[4,3-
a][1,4]diazepine.
Diclazepam (7-chloro-5-(2-chloro-5-(2- 2789 I
chlorophenyl)-1-methyl-1,3-dihydro-2H-
benzo[e][1,4]diazepin-2-one.
JWH-250 (1-Pentyl-3-(2- 6250 I
methoxyphenylacetyl) indole).
SR-18 (Also known as RCS-8) (1- 7008 I
Cyclohexylethyl-3-(2-
methoxyphenylacetyl) indole).
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1- 7010 I
oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-
indazole-3-carboxamide).
5-Fluoro-UR-144 and XLR11 [1-(5-Fluoro- 7011 I
pentyl)1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone.
AB-FUBINACA (N-(1-amino-3-methyl-1- 7012 I
oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-
indazole-3-carboxamide).
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole). 7019 I
FUB-AMB, MMB-FUBINACA, AMB-FUBINACA (2- 7021 I
(1-(4-fluorobenzyl)-1Hindazole-3-
carboxamido)-3-methylbutanoate).
AB-PINACA (N-(1-amino-3-methyl-1- 7023 I
oxobutan-2-yl)-1-pentyl-1H-indazole-3-
carboxamide).
THJ-2201 ([1-(5-fluoropentyl)-1H-indazol- 7024 I
3-yl](naphthalen-1-yl)methanone).
5F-AB-PINACA (N-(1-amino-3-methyl-1- 7025 I
oxobutan-2-yl)-1-(5-fluropentyl)-1H-
indazole-3-carboximide).
AB-CHMINACA (N-(1-amino-3-methyl-1- 7031 I
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-
indazole-3-carboxamide).
5F-ADB, 5F-MDMB-PINACA (Methyl 2-(1-(5- 7034 I
fluoropentyl)-1H-indazole-3-
carboxamido)-3,3-dimethylbutanoate).
5F-MDMB-PICA (methyl 2-(1-(5- 7041 I
fluoropentyl)-1H-indole-3-carboxamido)-
3,3-dimethylbutanoate).
MDMB-CHMICA, MMB-CHMINACA (Methyl 2-(1- 7042 I
(cyclohexylmethyl)-1H-indole-3-
carboxamido)-3,3-dimethylbutanoate).
APINACA and AKB48 (N-(1-Adamantyl)-1- 7048 I
pentyl-1H-indazole-3-carboxamide).
5F-APINACA, 5F-AKB48 (N-(adamantan-1-yl)- 7049 I
1-(5-fluoropentyl)-1H-indazole-3-
carboxamide).
JWH-081 (1-Pentyl-3-(1-(4- 7081 I
methoxynaphthoyl) indole).
4-CN-CUML-BUTINACA, 4-cyano-CUMYL- 7089 I
BUTINACA, 4-CN-CUMYL BINACA, CUMYL-4CN-
BINACA, SGT-78 (1-(4-cyanobutyl)-N-(2-
phenylpropan-2-yl)-1H-indazole-3-
carboxamide).
SR-19 (Also known as RCS-4) (1-Pentyl-3- 7104 I
[(4-methoxy)-benzoyl] indole).
JWH-018 (also known as AM678) (1-Pentyl- 7118 I
3-(1-naphthoyl)indole).
JWH-122 (1-Pentyl-3-(4-methyl-1- 7122 I
naphthoyl) indole).
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3- 7144 I
tetramethylcyclopropyl)methanone.
JWH-073 (1-Butyl-3-(1-naphthoyl)indole). 7173 I
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1- 7200 I
naphthoyl)indole).
AM2201 (1-(5-Fluoropentyl)-3-(1- 7201 I
naphthoyl) indole).
JWH-203 (1-Pentyl-3-(2- 7203 I
chlorophenylacetyl) indole).
PB-22 (Quinolin-8-yl 1-pentyl-1H-indole- 7222 I
3-carboxylate).
5F-PB-22 (Quinolin-8-yl 1-(5- 7225 I
fluoropentyl)-1H-indole-3-carboxylate).
N-ethylhexedrone 7246 I N............... 7246 I
Alpha-ethyltryptamine................... 7249 I
Ibogaine................................ 7260 I
2-(ethylamino)-2-(3- 7286 I
methoxyphenyl)cyclohexan-1-one
(methoxetamine).
CP-47,497 (5-(1,1-Dimethylheptyl)-2- 7297 I
[(1R,3S)-3-hydroxycyclohexyl-phenol).
CP-47,497 C8 Homologue (5-(1,1- 7298 I
Dimethyloctyl)-2-[(1R,3S)3-
hydroxycyclohexyl-phenol).
Lysergic acid diethylamide.............. 7315 I
2C-T-7 (2,5-Dimethoxy-4-(n)- 7348 I
propylthiophenethylamine.
Marihuana Extract....................... 7350 I
Marihuana............................... 7360 I
Tetrahydrocannabinols................... 7370 I
Mescaline............................... 7381 I
2C-T-2 (2-(4-Ethylthio-2,5- 7385 I
dimethoxyphenyl) ethanamine ).
3,4,5-Trimethoxyamphetamine............. 7390 I
4-Bromo-2,5-dimethoxyamphetamine........ 7391 I
[[Page 24863]]
4-Bromo-2,5-dimethoxyphenethylamine..... 7392 I
4-Methyl-2,5-dimethoxyamphetamine....... 7395 I
2,5-Dimethoxyamphetamine................ 7396 I
JWH-398 (1-Pentyl-3-(4-chloro-1- 7398 I
naphthoyl) indole).
2,5-Dimethoxy-4-ethylamphetamine........ 7399 I
3,4-Methylenedioxyamphetamine........... 7400 I
3,4-Methylenedioxy-N-ethylamphetamine... 7404 I
3,4-Methylenedioxymethamphetamine....... 7405 I
4-Methoxyamphetamine.................... 7411 I
5-Methoxy-N-N-dimethyltryptamine........ 7431 I
Alpha-methyltryptamine.................. 7432 I
Bufotenine.............................. 7433 I
Diethyltryptamine....................... 7434 I
Dimethyltryptamine...................... 7435 I
Psilocybin.............................. 7437 I
Psilocyn................................ 7438 I
5-Methoxy-N,N-diisopropyltryptamine..... 7439 I
N-Ethyl-1-phenylcyclohexylamine......... 7455 I
1-(1-Phenylcyclohexyl)pyrrolidine....... 7458 I
1-[1-(2-Thienyl)cyclohexyl]piperidine... 7470 I
N-Benzylpiperazine...................... 7493 I
4-MePPP (4-Methyl- 7498 I
alphapyrrolidinopropiophenone).
2C-D (2-(2,5-Dimethoxy-4-methylphenyl) 7508 I
ethanamine).
2C-E (2-(2,5-Dimethoxy-4-ethylphenyl) 7509 I
ethanamine).
2C-I 2-(4-iodo-2,5-dimethoxyphenyl) 7518 I
ethanamine).
2C-C 2-(4-Chloro-2,5-dimethoxyphenyl) 7519 I
ethanamine).
2C-N (2-(2,5-Dimethoxy-4-nitro-phenyl) 7521 I
ethanamine).
2C-P (2-(2,5-Dimethoxy-4-(n)- 7524 I
propylphenyl) ethanamine).
2C-T-4 (2-(4-Isopropylthio)-2,5- 7532 I
dimethoxyphenyl) ethanamine).
MDPV (3,4-Methylenedioxypyrovalerone)... 7535 I
25B-NBOMe (2-(4-bromo-2,5- 7536 I
dimethoxyphenyl)-N-(2-methoxybenzyl)
ethanamine).
25C-NBOMe (2-(4-chloro-2,5- 7537 I
dimethoxyphenyl)-N-(2-methoxybenzyl)
ethanamine).
25I-NBOMe (2-(4-iodo-2,5- 7538 I
dimethoxyphenyl)-N-(2-methoxybenzyl)
ethanamine).
Methylone (3,4-Methylenedioxy-N- 7540 I
methylcathinone).
Butylone................................ 7541 I
Pentylone............................... 7542 I
N-Ethypentylone, ephylone (1-(1,3- 7543 I
benzodioxol-5-yl)-2-(ethylamino)-pentan-
1-one).
alpha-pyrrolidinopentiophenone ([alpha]- 7545 I
PVP).
alpha-pyrrolidinobutiophenone ([alpha]- 7546 I
PBP).
Ethylone................................ 7547 I
AM-694 (1-(5-Fluoropentyl)-3-(2- 7694 I
iodobenzoyl) indole).
Codeine-N-oxide......................... 9053 I
Desomorphine............................ 9055 I
Dihydromorphine......................... 9145 I
Difenoxin............................... 9168 I
Heroin.................................. 9200 I
Morphine-N-oxide........................ 9307 I
Nicomorphine............................ 9312 I
Normorphine............................. 9313 I
Pholcodine.............................. 9314 I
Drotebanol.............................. 9335 I
U-47700 (3,4-dichloro-N-[2- 9547 I
(dimethylamino)cyclohexyl]-N-
methylbenzamide).
AH-7921 (3,4-dichloro-N-[(1- 9551 I
dimethylamino)cyclohexylmethyl]benzamid
e)).
MT-45 (1-cyclohexyl-4-(1,2- 9560 I
diphenylethyl)piperazine)).
Acetylmethadol.......................... 9601 I
Alphameprodine.......................... 9604 I
Alphamethadol........................... 9605 I
Benzethidine............................ 9606 I
Betameprodine........................... 9608 I
Clonitazene............................. 9612 I
Dextromoramide.......................... 9613 I
Isotonotazene (N,N-diethyl-2-(2-(4 9614 I
isopropoxybenzyl)-5-nitro-1H-
benzimidazol-1-yl)ethan-1-amine).
Dimenoxadol............................. 9617 I
Dimepheptanol........................... 9618 I
Dimethylthiambutene..................... 9619 I
Dioxaphetyl butyrate.................... 9621 I
Dipipanone.............................. 9622 I
Etonitazene............................. 9624 I
Ketobemidone............................ 9628 I
Levomoramide............................ 9629 I
Noracymethadol.......................... 9633 I
Norlevorphanol.......................... 9634 I
Normethadone............................ 9635 I
[[Page 24864]]
Piritramide............................. 9642 I
Properidine............................. 9644 I
Racemoramide............................ 9645 I
1-Methyl-4-phenyl-4-propionoxypiperidine 9661 I
Tilidine................................ 9750 I
Metonitazene (N,N-diethyl-2-(2-(4- 9757 I
methoxybenzyl)-5-nitro-1Hbenzimidazol-1-
yl)ethan-1-amine.
Protonitazene (N,N-diethyl-2-(5-nitro-2- 9759 I
(4-propoxybenzyl)-1H-benzimidazol-1-
yl)ethan-1-amine).
+Para-Fluorofentanyl.................... 9812 I
3-Methylfentanyl........................ 9813 I
Alpha-methylfentanyl.................... 9814 I
Acetyl Fentanyl (N-(1-phenethylpiperidin- 9821 I
4-yl)-N-phenylacetamide).
Butyryl Fentanyl........................ 9822 I
4-Fluoroisobutyryl fentanyl (N-(4- 9824 I
fluorophenyl)-N-(1-phenethylpiperidin-4-
yl)isobutyramide).
Beta-hydroxyfentanyl.................... 9830 I
Beta-hydroxy-3-methylfentanyl........... 9831 I
3-Methylthiofentanyl.................... 9833 I
Furanyl fentanyl (N-(1- 9834 I
phenethylpiperidin-4-yl)-N-phenylfuran-
2-carboxamide).
Thiofentanyl............................ 9835 I
Beta-hydroxythiofentanyl................ 9836 I
Ocfentanil.............................. 9838 I
beta'-Phenyl fentanyl (N-(1- 9842 I
phenethylpiperidin-4-yl)-N,3-
diphenylpropanamide; also known as
[beta]'-phenyl fentanyl; 3-
phenylpropanoyl fentanyl).
N-(1-phenethylpiperidin-4-yl)-N- 9843 I
phenyltetrahydrofuran-2-carboxamide.
Crotonyl fentanyl ((E-N-(1- 9844 I
phenethylpiperidin-4-yl)-N-phenylbut-2-
enamide).
Cyclopropyl Fentanyl.................... 9845 I
ortho-Fluorobutyryl fentanyl (N-(2- 9846 I
fluorophenyl)-N-(1-phenethylpiperidin-4-
yl)butyramide; also known as 2-
fluorobutyryl fentanyl).
Fentanyl related-compounds as defined in 9850 I
21 CFR 1308.11(h).
Amphetamine............................. 1100 II
Methamphetamine......................... 1105 II
Lisdexamfetamine........................ 1205 II
Phenmetrazine........................... 1631 II
Amobarbital............................. 2125 II
Pentobarbital........................... 2270 II
Secobarbital............................ 2315 II
Glutethimide............................ 2550 II
Nabilone................................ 7379 II
Phencyclidine........................... 7471 II
ANPP (4-Anilino-N-phenethyl-4- 8333 II
piperidine).
Norfentanyl (N-phenyl-N-(piperidin-4-yl) 8366 II
propionamide).
Phenylacetone........................... 8501 II
Alphaprodine............................ 9010 II
Cocaine................................. 9041 II
Codeine................................. 9050 II
Dihydrocodeine.......................... 9120 II
Oxycodone............................... 9143 II
Hydromorphone........................... 9150 II
Diphenoxylate........................... 9170 II
Ecgonine................................ 9180 II
Ethylmorphine........................... 9190 II
Hydrocodone............................. 9193 II
Levomethorphan.......................... 9210 II
Levorphanol............................. 9220 II
Isomethadone............................ 9226 II
Meperidine.............................. 9230 II
Meperidine intermediate-A............... 9232 II
Meperidine intermediate-B............... 9233 II
Meperidine intermediate-C............... 9234 II
Oliceridine (N-[(3-methoxythiophen- 9245 II
2yl)methyl] ({2-[9r)-9-(pyridin-2-yl)-6-
oxaspiro[4.5] decan-9-yl] ethyl
{time{time} )amine fumarate).
Methadone............................... 9250 II
Methadone intermediate.................. 9254 II
Dextropropoxyphene, bulk (non-dosage 9273 II
forms).
Morphine................................ 9300 II
Oripavine............................... 9330 II
Thebaine................................ 9333 II
Levo-alphacetylmethadol................. 9648 II
Oxymorphone............................. 9652 II
Noroxymorphone.......................... 9668 II
Phenazocine............................. 9715 II
Racemethorphan.......................... 9732 II
Alfentanil.............................. 9737 II
Remifentanil............................ 9739 II
[[Page 24865]]
Sufentanil.............................. 9740 II
Carfentanil............................. 9743 II
Tapentadol.............................. 9780 II
Fentanyl................................ 9801 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
distribution for analytical testing purposes. No other activities for
these drug codes are authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-07525 Filed 4-8-24; 8:45 am]
BILLING CODE P
